2022 marked the end of Novartis’ second three-year performance cycle under Narasimhan, who ascended from chief medical officer at the company to CEO in 2018. Novartis’ most recent performance ...

In March 2022, global pharmaceutical company Novartis published its first-ever Novartis in Society integrated report. That means the company combined its report on annual financial performance ...

The global DTP vaccines market is expected to grow from $4.00 billion in 2021 to $4.45 billion in 2022 at a compound annual growth rate (CAGR) of 11.0%. The growth is mainly due to the companies ...

Basel, March 4, 2022 - Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting (AGM). In accordance with ...

Roche is forecast to tally $52.6 billion in 2022 prescription drug sales, representing a 4% annual expansion over 2015’s total of $38.7 billion, according to EvaluatePharma’s new World Preview ...